Bernstein has recommended investing in Zydus, Lupin, and Sun Pharma, predicting a potential $75 billion growth in India's biopharmaceutical sector over the next decade. The firm believes that innovation, AI integration, and focus on niche therapies could propel this growth, with Zydus being their top choice. Biocon and Mankind Pharma were rated as less promising investments.

The Nifty Pharma index has significantly outperformed the broader market, increasing by 11% over the past month while the Nifty 50 experienced a decline of 3.6%. Notable standouts in this sector include Gland Pharma with a impressive 27% gain, Laurus Labs at 23%, and Biocon showing a 21% rise.

Pharmaceutical companies IPCA Labs, Biocon, Laurus Labs, Gland Pharma, Aurobindo, Sun Pharma, Wockhardt, Lupin, Divi's, Zydus, Torrent, JB Chem, Glenmark, and Ajanta have surged to their highest levels in the past year. Other notable gains were seen among stocks like these.

Biocon Limited has broken through an ascending triangle pattern, indicating a potential bullish phase, backed by increased trading volumes and position above the 20-day Simple Moving Average (SMA). Additionally, the expanding Bollinger Bands coupled with rising trendline support suggests strong upward momentum for Biocon.

Biocon Limited's Q4 FY26 results show a 12% growth in biosimilars and a 13% increase in generics compared to last year. The company is now concentrating on debt reduction, aiming to capitalize on interest cost benefits and increasing free cash flow to improve its financial leverage.

Recommended stocks for May 14, 2026 include ONGC, NTPC Green, and Biocon due to favorable technical and sectoral trends. Anticipated prices are ONGC at Rs 320, NTPC Green at Rs 120, and Biocon at Rs 430, with suggested stop losses for risk management.

Biocon's shares have seen a 10% increase in the past three days, approaching their 52-week high of ₹424.95. The surge was driven by Health Canada's approval of Biocon Pharma's micafungin injection, which strengthens its biosimilars portfolio. Additionally, Q4FY26 reported a 13% year-on-year growth in revenue. This outperformance was noticeable compared to Sensex during the same period.

Biocon Pharmaceuticals has received approval from Health Canada for Micafungin, a treatment for fungal infections and prevention of Candida infections in stem cell transplant patients. This move strengthens the company's biosimilar portfolio by adding another effective medication to their offerings.

Biocon anticipates enhanced profits in their generic drugs sector due to new product stability and increased usage. Attention is also given to the execution strategy within their contract research and manufacturing organization, Syngene.

Goldman Sachs has set a new target price for Biocon at INR 375 and remains neutral on the stock, suggesting neither a buy nor sell recommendation at this time.

Biocon plans to boost its presence of the biosimilar Aspart in the U.S. market by focusing on gaining full market control within certain closed-network health providers, aiming for significant growth by mid-2027.

Biocon aims to lower its debt by approximately $1.1 billion - $1.2 billion using its cash reserves, with hopes for increased earnings in the future, primarily due to new product launches beyond FY27-FY28.

Biocon Ltd announces a final dividend of INR 0.50 per share for FY26, boosting investor confidence. The stock reached an intraday high of INR 396.45 on BSE, demonstrating strong market sentiment towards the biotech giant's performance.

Biocon's Q4 revenue has increased by 10%, reaching INR 4,517 crores. The company is aiming for a transition into the execution phase in fiscal year 2026-2027.

Biocon's FY27 outlook indicates significant growth due to increased production of biosimilars. This suggests that the company's focus on these cost-effective alternatives to original biologic drugs is paying off.

Biocon's Q4 earnings show a 57% decrease in net profit at ₹199 crore, largely due to a drop in EBITDA and a 2.3% increase in revenue. The company attributes this performance to robust growth in its biosimilar products, particularly in the US market with focus on oncology and Stelara biosimilar launches.

Biocon aims to secure new partnerships for their biosimilar lineup by the fiscal year 2026, with CEO Shreehas Tambe emphasizing the importance of capitalizing on a global presence to bolster existing therapeutic segments.

Today's focus stocks are Lupin, Biocon, and Bharat Forge. Also, keep an eye on Pace Digitek, Cochin Shipyard, Lenskart, and PNC Infrastructure for potential market movements.

Biocon has announced its approval of the fiscal year 2026 audited results and a recommended final dividend of 10%. The company also plans to switch auditors and has acquired a 2% stake in a subsidiary. Additionally, new leadership has been appointed.

Biocon's Q4 profits declined by 63.5% Year-over-Year (YoY) to Rs 126 crore due to a high base effect and exceptional expenses. Despite this, revenue increased by 2.3% YoY to Rs 4,517 crore. The biosimilar division demonstrated a robust 12% growth, compensating for a modest 2% expansion in the CRDMO sector.

Biocon's Q4 profit experienced a significant drop of 57%, reaching ₹199 crore, primarily due to exceptional costs amounting to ₹80.4 crore. A decline in revenue to ₹4516.6 crore can be attributed to the impact of new labour code provisions.

Biocon is set to strengthen its biologics division with a 2% equity acquisition in Biocon Biologics, valued at approximately INR 331 crore through a share swap. This strategic move aims to foster a more integrated and simplified corporate structure.

Biocon's Q4 earnings report shows a decrease in EBITDA to ₹10.2 billion, compared to ₹10.8 billion in the same quarter last year. The EBITDA margin also took a dip, falling from 24.4% to 22.6% over the same period. This suggests a potential narrowing of profit margins for Biocon in Q4.

Today marks the release of Q4 results for major companies including SBI, Titan, ABB India, BoB, MCX, Biocon, Dabur, Lupin, and MRF. Stocks to watch out for include Ujjivan Small Finance Bank, Kalyan Jewellers, BSE, KVB, TCP, ACME, with Hyundai and Swiggy also gaining attention.

Bharat Forge, Biocon, MRF, and other listed companies like Dabur, Escorts Kubota, Lupin, and Pidilite are set to announce their Q4 earnings today. Notable projections include a profit of approximately Rs 369.8 crore for Bharat Forge, Rs 223.2 crore for Biocon, Rs 1,202 crore for Lupin, and a revenue of around Rs 8,112 crore for MRF. Dabur is expected to maintain a margin at 15.1%.

Promoter stakes for Godrej Properties and Adani Energy have increased in the latest quarter, while Biocon and BHEL have seen decreases in promoter ownership. Overall, there's been a shift in shareholding patterns within the Nifty 50, with foreign institutional investors (FIIs) reducing their holdings and domestic institutional investors (DIIs) boosting their positions across various indices.

Biocon, Bajaj Auto, and BSE's Q4 results have drawn attention from the market. Awaiting further actions as updates are released in the #StockInNews.

Biocon's shares experienced a 1% uptick following the announcement that Kiran Mazumdar-Shaw appointed her niece as her successor, indicating potential continuity in leadership for the company.

Biocon expects increased competition to impact profit margins in their insulin glargine business, as reported by NDTV.

Biocon's board is planning to raise funds for Biocon Biologics by selling new shares, subject to shareholder approval via a postal ballot. More information can be found on Biocon's official website.

Investors may consider buying ICICI Bank shares when prices drop, as suggested by experts on NDTV Profit. On the other hand, it might be wise to sell off Kalyan Jewellers stocks at this time. For Zydus, Vedanta, Biocon, and United Spirits, it's recommended to hold onto current positions, according to the same experts.

Biocon has scheduled a board meeting for May 7, 2026, to discuss and approve Q4 FY26 results, dividend, and regular matters. The earnings call for analysts and investors will take place the next day on May 8, with recordings and transcripts to be made available after the event.

Biocon secures Canadian approval for its biosimilar drugs Bosaya and Vevzuo, aimed at addressing osteoporosis and cancer-related bone issues in approximately 2 million patients.

HSBC upholds its bullish stance on Biocon, predicting a price of ₹425, based on positive factors like debt reduction, corporate simplification, successful biosimilar launches, increased market shares, and enhanced cash flows.

Vaishali Parekh suggests buying IFCI, Biocon, and JSW Energy for short-term trading, with the Nifty 50 finding support at 23,800 and facing resistance at 24,300. The Bank Nifty encounters resistance at 57,000 and support at 53,500, while broader markets are under pressure due to weak global signals.

Biocon is shifting its focus towards global markets, particularly biosimilars and GLP-1 therapies, to steer clear of India's semaglutide price competition. These biosimilars account for nearly 58% of the company's revenue, with oncology and insulin expansion identified as key growth areas, offering a potential market opportunity worth $260 billion.

Keep an eye on notable stocks such as Infosys, Biocon, Swan Defense, Life Insurance Corporation (LIC), and Aditya Birla Real Estate, which are currently attracting attention in the market.

Biocon Pharma has received FDA approval for its Dapagliflozin tablets in two strengths (5mg and 10mg), marking a significant step forward in their drug offerings for diabetes management.

Biocon has conducted a large share transaction on the National Stock Exchange, selling 1.37 million shares at around Rs. 349 each, resulting in an overall value of approximately Rs. 47.97 crores.

Biocon Ltd will attend the HSBC Global Investment Summit in Hong Kong and an investor roadshow in Singapore next April. Notably, the company has stated that it won't reveal any undisclosed price-sensitive information during these meetings. Further details can be found on Biocon's official website.